NCT01466569View on ClinicalTrials.gov

An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Solid Tumor of Epithelial OriginGastric Cancer
Interventions
DRUG

AbGn-7

Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks

DRUG

AbGn-7

Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks

Trial Locations (4)

104

MacKay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

19046

Fox Chase Cancer Center, Rockledge

78229

The University of Texas Health Science Center-CTRC, San Antonio

All Listed Sponsors
lead

AbGenomics B.V Taiwan Branch

INDUSTRY

NCT01466569 - An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter